SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

8 Oct 2015 07:00

RNS Number : 5861B
Victrex PLC
08 October 2015
 



 

 

 

 

 

 

8 October 2015

 

Victrex plc - Full year pre-close trading update

 

"A good finish to 2015"

 

Victrex plc, an innovative world leader in high performance polymer solutions, today announces its full year pre-close trading update for the financial year ended 30 September 2015, ahead of its preliminary results on 8 December 2015.

 

Victrex delivered a good finish to 2015, with overall performance in line with our expectations, including a robust fourth quarter (Q4). For the year as a whole, the value of our balanced portfolio helped to drive growth and fully overcome headwinds including weaker sales in Oil & Gas, the effects of US Spine market consolidation on our Invibio medical business and the significant impact from foreign currency this year.

 

On a reported basis, full year Group revenue of £263.5m was 4% ahead of the prior year (FY 2014: £252.6m), with Q4 Group revenue of £68.7m being flat on the prior year period. Foreign currency, at a profit level, was a headwind of approximately £8m for the full year, which we will fully overcome.

 

At a volume level, full year Group sales volume of 4,217 tonnes was 19% ahead of the prior year (FY 2014: 3,551 tonnes). Q4 Group sales volume of 1,119 tonnes was 6% ahead of the prior year period (Q4 2014: 1,056 tonnes). Sales volumes reflect our overall momentum in VPS remaining positive during the fourth quarter, with growth across Aerospace, Automotive, General Industrial and strong Consumer Electronics volumes offsetting Oil & Gas, as previously communicated.

 

Invibio performance was in line with our previous guidance, with full year revenue of £50.5m being 5% down compared to the prior year (FY 2014: £53.4m). This reflects the effects of consolidation in the US Spine market.

 

Outlook

Our overall growth momentum remains positive as we start our new financial year. Whilst we are mindful of the continuing weakness in Oil & Gas and the need to improve Invibio performance in 2016, our balanced portfolio keeps us well placed to continue driving growth and creating value, in line with our long term strategy.

 

Enquiries:

 

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 1253 898121

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

David Hummel, Chief Executive +44 (0) 1253 897700

 

Pendomer Communications:

Charles Armitstead +44 (0) 203 603 5220

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions focused on the Aerospace, Automotive, Electronics, Energy and Medical markets. Every day, millions of people rely on products or applications which contain our polymers, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we are delivering leading edge solutions to shape future performance for our customers and our markets, and to drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGGQWUUPAGAM
Date   Source Headline
29th Apr 20221:16 pmRNSTotal Voting Rights
21st Apr 20222:50 pmRNSHolding(s) in Company
20th Apr 202212:20 pmRNSDirector/PDMR Shareholding
5th Apr 20227:00 amRNSDirectorate Change
31st Mar 202210:39 amRNSTotal Voting Rights
22nd Mar 202211:35 amRNSDirector/PDMR Shareholding
18th Mar 202210:09 amRNSHolding(s) in Company
17th Mar 202212:21 pmRNSDirector/PDMR Shareholding
15th Mar 20223:07 pmRNSAdditional Listing
28th Feb 202210:46 amRNSTotal Voting Rights
22nd Feb 20221:14 pmRNSDirector/PDMR Shareholding
17th Feb 202212:30 pmRNSDirector/PDMR Shareholding
15th Feb 202212:12 pmRNSHolding(s) in Company
11th Feb 202212:21 pmRNSResult of AGM
11th Feb 20227:00 amRNSAGM & Q1 Interim Management Statement
10th Feb 20222:06 pmRNSDirector/PDMR Shareholding
10th Feb 202210:15 amRNSHolding(s) in Company
31st Jan 202210:23 amRNSTotal Voting Rights
28th Jan 20223:23 pmRNSHolding(s) in Company
24th Jan 20223:54 pmRNSHolding(s) in Company
20th Jan 20229:21 amRNSAdditional Listing
18th Jan 20223:11 pmRNSDirector/PDMR Shareholding
6th Jan 20222:14 pmRNSAnnual Report and Accounts
6th Jan 20229:53 amRNSDirector/PDMR Shareholding
31st Dec 20219:00 amRNSTotal Voting Rights
17th Dec 20213:59 pmRNSHolding(s) in Company
17th Dec 202112:01 pmRNSDirector/PDMR Shareholding
16th Dec 20211:06 pmRNSDirector/PDMR Shareholding
13th Dec 202111:20 amRNSDirector/PDMR Shareholding
6th Dec 20217:00 amRNSVictrex plc – Preliminary Results 2021
1st Dec 20213:48 pmRNSBlock listing Interim Review
30th Nov 202111:39 amRNSTotal Voting Rights
18th Nov 20212:12 pmRNSDirector Declaration
17th Nov 202112:17 pmRNSDirector/PDMR Shareholding
9th Nov 20211:51 pmRNSDirector Declaration - Replacement
9th Nov 20219:00 amRNSDirector Declaration
29th Oct 20219:25 amRNSTotal Voting Rights
21st Oct 20217:00 amRNSVictrex signs up to SBTi
19th Oct 202111:13 amRNSDirector/PDMR Shareholding
15th Oct 20217:00 amRNSDirectorate Change
14th Oct 20217:00 amRNSTechnipFMC to acquire Victrex’s Magma equity
30th Sep 20212:22 pmRNSTotal Voting Rights
20th Sep 20217:00 amRNSChair-designate appointment
17th Sep 202110:51 amRNSDirector/PDMR Shareholding
31st Aug 202110:23 amRNSTotal Voting Rights
18th Aug 20214:11 pmRNSDirector/PDMR Shareholding
30th Jul 202112:18 pmRNSTotal Voting Rights
19th Jul 202110:21 amRNSDirector/PDMR Shareholding
9th Jul 20217:00 amRNSVictrex Q3 Interim Management Statement
30th Jun 202110:23 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.